Bombay HC Holds ZEROVOL-P Infringes ZERODOL Trademark, Imposes Rs 15 Lakh Costs

Introduction

In a significant ruling on trademark protection in the pharmaceutical sector, the Bombay High Court has decreed that Anrose Pharma's use of the mark 'ZEROVOL-P' constitutes infringement and passing off of IPCA Laboratories Limited's registered trademark 'ZERODOL'. Justice Arif S. Doctor, presiding over Commercial IP Suit No. 77 of 2013, granted a permanent injunction against Anrose Pharma, restrained the company from further use of the impugned mark, ordered delivery up of infringing materials for destruction, and imposed exemplary costs of ₹15 lakhs. This decision underscores the court's stringent approach to deceptive similarity in medicinal trademarks, emphasizing public health risks associated with confusion among pharmaceutical products. The suit, initiated in 2013, proceeded undefended after Anrose Pharma failed to appear despite service of summons, highlighting the perils of non-engagement in intellectual property disputes.

The judgment, pronounced on January 5, 2026, after being reserved on December 22, 2025, reinforces established principles of trademark law under the Trade Marks Act, 1999, while applying a heightened scrutiny due to the nature of the goods involved. For legal professionals, this case serves as a reminder of the mandatory cost provisions under Section 35 of the Code of Civil Procedure (CPC), as amended by the Commercial Courts Act, 2015, particularly in commercial suits involving potential harm to public interest.

Case Background

IPCA Laboratories Limited, a prominent pharmaceutical company incorporated under the Companies Act, 1913, with its registered office in Mumbai, has long been associated with the trademark 'ZERODOL'. The company coined and adopted the mark in September 1992 for medicinal and pharmaceutical preparations, particularly those for pain relief and management. Commercial use commenced in 2003, and IPCA secured registration under No. 582203 in Class 5, which remains valid and subsisting. Over the years, IPCA expanded its product line to include over 10 variants, such as ZERODOL-P, ZERODOL-PT, ZERODOL-S, ZERODOL-MR, and ZERODOL-TH, backed by substantial promotional expenditures and annual sales turnovers that underscore the mark's acquired distinctiveness and goodwill.

The dispute arose in October 2013 when IPCA discovered Anrose Pharma manufacturing and selling a pain relief product under the mark 'ZEROVOL-P'. IPCA procured samples along with invoices, revealing the defendant's use of the impugned mark for identical goods—pharmaceutical preparations for pain management. Promptly, IPCA filed the suit seeking a permanent injunction for trademark infringement under Sections 29(2) and 29(4) of the Trade Marks Act, 1999, and passing off, alleging that 'ZEROVOL-P' was deceptively similar to 'ZERODOL', leading to inevitable confusion among consumers, medical professionals, and the trade.

The procedural timeline was marked by swift interim reliefs. On October 29, 2013, the court granted ex-parte ad-interim injunctions restraining Anrose from using the mark. Leave under Clause XIV of the Letters Patent was granted on November 21, 2013, and the ad-interim order was confirmed on December 9, 2013. Summons were served on Anrose on January 17, 2014, but the defendant neither filed a written statement nor appeared, resulting in the suit being placed on the undefended board on July 24, 2017. Evidence was led through IPCA's witness, Mr. Harish Kamath, the company secretary, whose affidavit and document compilation went unchallenged. The matter proceeded to judgment after hearings in late 2025, culminating in the decree.

The core legal questions before the court included: (1) Whether 'ZEROVOL-P' was deceptively similar to 'ZERODOL' visually, phonetically, and structurally, warranting infringement; (2) Whether the defendant's use constituted passing off, given the identical nature of goods and the plaintiff's established reputation; (3) The appropriate reliefs, including injunction, delivery up, damages, and costs, considering the commercial nature of the suit and the defendant's non-participation.

This background illustrates a classic intellectual property conflict in the highly regulated pharmaceutical industry, where trademarks not only protect commercial interests but also safeguard public health by preventing erroneous prescriptions or self-medication due to brand confusion.

Arguments Presented

As the suit was undefended, arguments were presented solely on behalf of IPCA Laboratories Limited, with the court drawing adverse inferences from Anrose Pharma's absence and failure to contest the evidence. IPCA's counsel, Mr. Minesh Andharia along with Mr. Jay Shah, instructed by Krishna & Saurastri Associates LLP, meticulously outlined the plaintiff's case, emphasizing the deceptive nature of the impugned mark and the defendant's mala fide intent.

IPCA contended that 'ZERODOL' had acquired substantial goodwill through continuous, extensive, and exclusive use since 2003, supported by sales invoices (Exhibits F1 to F20), promotional materials, and certified sales turnover statements. The registration certificate (Exhibit A1) established prima facie statutory rights. The discovery of 'ZEROVOL-P' in October 2013, evidenced by product samples (Exhibit P-10) and invoices (Exhibit P-11), demonstrated Anrose's subsequent and dishonest adoption, aimed at trading on IPCA's reputation.

Key factual points included the structural similarity: both marks shared the prefix 'ZERO' followed by phonetically akin suffixes—'DOL' and 'VOL'—with the addition of '-P' in both variants, creating near-identical visual and auditory impressions. IPCA argued that, under settled law, trademarks must be assessed holistically from the viewpoint of an average consumer with imperfect recollection, not through side-by-side microscopic comparison. Given the medicinal context, even a minimal likelihood of confusion posed grave risks, such as incorrect dosage or adverse reactions, justifying stricter scrutiny.

Legally, IPCA invoked principles from Supreme Court precedents to substantiate deceptive similarity. Reliance was placed on K.R. Chinna Krishna Chettiar v. Shri Ambal & Co. (1969) 2 SCC 131, where phonetic affinity between 'ANDAL' and 'AMBAL' led to a finding of likely deception despite no visual resemblance, stressing comparison via ear and eye. Similarly, in Hiralal Prabhudas v. Ganesh Trading Company (AIR 1984 Bom 218), the Bombay High Court's Division Bench held that phonetic similarity between 'HIRALAL' and 'HIMATLAL', coupled with similar get-up, could confuse illiterate or average purchasers. Counsel extended this to cite Corn Products v. Shangrila Food Products (AIR 1960 SC 142) for overall structural and phonetic similarity in 'GLUCOVITA' and 'GLUVITA'; Amritdhara Pharmacy v. Satya Deo (AIR 1963 SC 449) for the 'wonderment' test indicating confusion; F. Hoffmann-La Roche & Co. v. Geoffrey Manners & Co. (AIR 1970 SC 2062) for holistic comparison without microscopic analysis; and Parle Products v. J.P. & Co. (AIR 1972 SC 1359) for focusing on broad, essential features likely to mislead usual purchasers.

IPCA further argued passing off, asserting misrepresentation, likelihood of damage to goodwill, and public deception. No honest concurrent use or justification was offered by Anrose, reinforcing bad faith. On reliefs, IPCA sought injunctions per prayer clauses (a), (b), and (d), punitive damages of ₹5 lakhs with 21% interest under Section 151 CPC, and exemplary costs under Section 35 CPC as amended, citing the defendant's conduct and public health imperative.

Anrose Pharma presented no arguments, cross-examination, or evidence, leading the court to note this as evidence of dishonest adoption. The plaintiff's uncontroverted affidavits and documents stood as conclusive proof.

Legal Analysis

Justice Arif S. Doctor's reasoning methodically applied trademark jurisprudence, affirming infringement under Sections 29(2) and 29(4) of the Trade Marks Act, 1999, and the common law tort of passing off. The court first validated IPCA's proprietary rights through the unchallenged registration and evidence of use since 2003, establishing prior and extensive adoption. Sales data and promotional expenditures confirmed acquired distinctiveness, positioning 'ZERODOL' as uniquely associated with IPCA.

Central to the analysis was deceptive similarity. The rival marks were deemed "virtually identical" visually and phonetically, with 'ZEROVOL-P' mimicking the dominant 'ZERO' prefix and similar 'DOL'/'VOL' endings, plus the shared '-P' suffix. Echoing K.R. Chinna Krishna Chettiar , the court emphasized holistic comparison from an average person's imperfect recollection, applying both visual and phonetic tests as in Hiralal Prabhudas . Phonetic affinity was pivotal, as in Amritdhara Pharmacy , where overall structure could induce 'wonderment' or confusion. The judge distinguished this from mere side-by-side differences, per Parle Products , focusing on essential features likely to mislead in retail settings.

The pharmaceutical context amplified the stakes. Unlike consumer goods, medicinal products demand stricter standards, as confusion risks public health—e.g., erroneous administration leading to harm. This aligned with F. Hoffmann-La Roche , mandating consideration of goods' nature, purchaser class (often hurried doctors or patients), and surrounding circumstances. Anrose's post-2013 adoption, without bona fide justification, evidenced bad faith, especially absent any defense under Sections 30-33 of the Act (e.g., no prior use or descriptive claim).

On passing off, the court found misrepresentation via similar marks on identical goods, inevitable confusion, and dilution of IPCA's goodwill, satisfying the classic triad from Reckitt & Colman v. Borden (though not cited, implied). Anrose's non-appearance fortified this, as no counter-evidence rebutted the plaintiff's case.

Precedents were integral: Corn Products reinforced phonetic and idea-based similarity; Hiralal highlighted average intelligence thresholds, even for semi-literate buyers. The court distinguished quashing defenses by noting Anrose's total inaction, unlike cases with honest adoption claims.

Reliefs were tailored: Injunction and delivery up followed statutory mandates, but damages were denied for lack of quantified loss proof, per evidential burdens in undefended suits. Costs, however, were exemplary under amended Section 35 CPC, factoring defendant's conduct and public risk, promoting deterrence in commercial IP litigation.

This analysis elucidates distinctions: Infringement is statutory (registered mark violation), passing off equitable (goodwill protection). For pharmaceuticals, societal impact elevates thresholds, potentially influencing future cases on generic-like marks.

Key Observations

The judgment is replete with incisive observations emphasizing rigorous trademark enforcement in sensitive sectors. Key excerpts include:

1. On deceptive similarity: "A perusal of the rival trade marks makes plain that they are virtually identical. The Defendant has not so much as even attempted to make out a case of honest or bona fide adoption of the mark ZEROVOL-P."

2. On the standard for medicinal products: "Equally, given that the impugned mark is virtually identical to the Plaintiff's registered trade mark and both are used in respect of medicinal or pharmaceutical products, the likelihood of confusion is imminent. Thus, the use by the Defendant of the impugned trade mark would almost certainly result in the goods of the Defendant being passed off as those of the Plaintiff."

3. On defendant's conduct: "The record reflects that the Defendant, in spite of being duly served, has chosen not to defend the Suit nor even cross-examine the Plaintiff's Witness. This conduct is an additional factor that makes it clear that the defendant's adoption of the impugned mark was dishonest and was actuated in bad faith."

4. On costs and public interest: "Moreover, the impugned products being medical products, a stricter order of costs must follow, as the Plaintiffs have profited at the potential risk to the public at large."

5. Holistic comparison principle: Referencing precedents, "Marks must be compared as a whole, the true test being whether the totality of the proposed trade mark is such that it is likely to cause deception or confusion or mistake in the minds of persons accustomed to the existing trade mark. Microscopic examinations not called for."

These quotes capture the court's rationale, blending statutory interpretation with equitable considerations.

Court's Decision

The Bombay High Court decreed the suit in favor of IPCA Laboratories Limited, granting all sought permanent injunctions. Specifically, Anrose Pharma was perpetually restrained from using 'ZEROVOL-P' or any deceptively similar mark on pharmaceutical preparations, infringing 'ZERODOL' (prayer clause a) or enabling passing off (prayer clause b). The defendant was ordered to deliver up all infringing articles—packaging, finished goods, dies, publicity materials—for destruction without compensation (prayer clause d).

No damages were awarded, as IPCA failed to prove specific losses despite claiming ₹5 lakhs. However, costs of ₹15,00,000 were imposed on Anrose, payable within 8 weeks, with 8% interest thereafter if delayed. This reflects Section 35 CPC's mandate for realistic, deterrent costs in commercial suits, considering the defendant's bad faith and public health implications.

The practical effects are multifaceted. For IPCA, the injunction safeguards its market position and brand integrity, preventing revenue loss from confusion. Anrose faces financial penalties and cessation of operations under the mark, underscoring litigation risks for non-responsive defendants. Broader implications include heightened deterrence against copycat trademarks in pharmaceuticals, encouraging vigilant IP monitoring by generics firms. Future cases may cite this for stricter confusion thresholds in health-related goods, potentially increasing exemplary awards to curb bad faith adoptions.

Legal professionals should note the interplay of Commercial Courts Act provisions, promoting efficient resolution while penalizing evasion. This ruling may spur amendments or guidelines on pharma trademarks, balancing innovation with consumer safety, and reinforces undefended suits' efficiency without compromising fairness.